Thanks to this program that TECH offers, you will be able to specialize in infectious pathologies and improve your skills as a pharmacist"

Among the infectious diseases of major global importance is malaria, endemic in more than 100 countries, where the goal is to reduce mortality by at least 20% from that observed in 2005 in at least 75 countries; Tuberculosis is another of the world's serious infectious problems, with some 8 million new cases per year and more than 1 million deaths, 20% of which are associated with HIV/AIDS infection, with problems of resistance to treatment and lack of compliance with treatment, which led the WHO to consider tuberculosis a global health emergency in 1993.
 
On the other hand, there is HIV/AIDS, the great pandemic, with more than 1.8 million adults dying in 2016 and more than 600,000 children under 15 infected in a single year, and for which current treatment (as well as prevention of vertical transmission) is beyond the reach of many in developing countries, with numerous cases of resistance to the antiretroviral drugs used already detected.
 
In addition to these three diseases it should be noted that despite scientific advances in Care Services science, public health development and the pharmaceutical and biotechnology industry, there are infectious diseases prevalent throughout the world that continue to have high morbidity and mortality rates, such as pneumonia, infectious diarrhoea, urinary tract infections, nosocomial infections, arbovirosis and intestinal parasitism.
 
All of this is alarming when one considers all the new infectious diseases that have emerged in the last 20 years with epidemic behaviour, such as severe acute respiratory syndrome, Chikingunya and more recently Zika.

This provides the opportunity to study a teaching program that brings together the most advanced and in-depth knowledge of important health problems in the field of infectious diseases and antimicrobial treatment, where a group of internationally experienced professors will provide students with the most up-to-date information for the diagnosis, treatment and care of patients with prevalent and life-threatening diseases.

In addition, this Professional master’s degree is updated so you will also have access to the most accurate and effective information on the functioning of Coronavirus infections froma pharmaceutical point of view"  

This Professional master’s degree in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics contains the most complete and up-to-date educational program on the market. The most important features of the training include: 

• The development of practical cases presented by experts in infectious diseases 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice 
• Practical exercises where self-assessment can be used to improve learning
• Its special emphasis on innovative methodologies  
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments 
• Content that is accessible from any fixed or portable device with an Internet connection  

TECH allows you to train with the best teaching staff and the best content without sacrificing maximum scientific rigor. This Professional Master's Degree is everything your career needs to start advancing" 

The program includes in its teaching staff, professionals from the sector who bring to this training the experience of their work, in addition to recognized specialists from prestigious reference societies and universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive training programmed to train in real situations.

This program is designed around Problem Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the academic year. For this purpose, the student will be assisted by an innovative interactive video system created by renowned and experienced experts.  

This program, updated in April 2020, is the best in the educational landscape in clinical infectious diseases and advanced therapeutics for pharmacists"

Get to know all the latest information on COVID-19 Don't miss the opportunity and get up-to-date on advances in the treatment of the infections to incorporate them into your daily Care Services practice"

The teaching program has been created by a group of professors and medical professionals from various medical specialities, with extensive medical, research and teaching experience in several countries in Africa, Central and South America, interested in integrating the latest and most up-to-date scientific knowledge of clinical infectious diseases and antimicrobial therapeutics, to ensure training and professional development to improve the daily clinical practice of professionals who care for patients or populations with infectious diseases. 

This Professional master’s degree in Clinical Infectious Diseases and Advanced Antibiotic Therapeutics contains the most complete and up-to-date scientific program on the market"  

Module 1. Epidemiology and Microbiology of Infectious Diseases

1.1.    Epidemiological, Economic, Social and Political Conditions in Continents Which Favor the Development of Infectious Diseases

1.1.1.    Africa
1.1.2.    America
1.1.3.    Europe and Asia

1.2.    New and Emerging Diseases By Continent

1.2.1.    Morbidity and Mortality From Infectious Diseases in Africa
1.2.2.    Morbidity and Mortality From Infectious Diseases in the Americas
1.2.3.    Infectious Disease Morbidity and Mortality in Asia
1.2.4.    Morbidity and Mortality From Infectious Diseases in Europe

1.3.    The Taxonomy Of Infectious Agents

1.3.1.    Viruses
1.3.2.    Bacteria
1.3.3.    Fungus
1.3.4.    Parasites

1.4.    Disease-producing Properties of Micro-organisms

1.4.1.    Mechanisms of Pathogenicity
1.4.2.    Mechanisms of Adhesion and Multiplication
1.4.3.    Mechanisms Enabling the Acquisition of Nutrients From The Host
1.4.4.    Mechanisms Inhibiting The Phagocytic Process
1.4.5.    Mechanisms For Evading The Immune Response

1.5.    Microscopy and Staining

1.5.1.    Microscopes and Types of Microscopes
1.5.2.    Composite Stains
1.5.3.    Acid-fast Micro-organism Stainings
1.5.4.    Staining to Demonstrate Cellular Structures

1.6.    Cultures and Growth of Micro-organisms

1.6.1.    General Culture Mediums
1.6.2.    Specific Culture Methods

1.7.    Effect of Chemical and Physical Agents on Micro-organisms

1.7.1.    Sterilisation and Disinfection
1.7.2.    Disinfectants and Antiseptics Used in Practice 

1.8.    Molecular Biology and its Importance for the Infectologist

1.8.1.    Bacterial Genetics
1.8.2.    Polymerase Chain Reaction Tests

1.9.    Indication and Interpretation of Microbiological Studies

Module 2. Cancer and Immunosuppression

2.1.    The Innate and Adaptive Immune Response

2.1.1.    Cells and Cytokines in Response to Infectious Agents
2.1.2.    Characteristics of the Innate Immune Response

2.2.    Immunosuppression in Different Conditions in Patients with Sepsis

2.2.1.    The role of Cytotoxics in Immunosuppression
2.2.2.    The role of Cytotoxics in Immunosuppression
2.2.3.    Infection in Transplant Patients

2.3.   The Oncohematological Patient with Sepsis

2.3.1.    Medullary Aplasia
2.3.2.    Neutropenia
2.3.3.    Infections in Patients with Cancer

2.4.    The Diabetic Patient with Sepsis

2.4.1.    The Immune System in Diabetes Mellitus
2.4.2.    Main Infections in the Diabetic Patient

2.5.    Comprehensive Approach to the Immuno-Compromised Patient with Sepsis

2.5.1.    Diagnostic Considerations
2.5.2.    Therapeutic Measures

2.6.    The Link Between Cancer and Micro-organisms

2.6.1.    Oncogenesis and Infection
2.6.2.    Virus and Cancer

    2.6.2.1. Epstein-Barr Virus
    2.6.2.2. Hepatitis B and C Viruses
    2.6.2.3. Human Immunodeficiency Virus
    2.6.2.4. T-cell Lymphoma/Leukaemia Viruses
    2.6.2.5. Kaposi's Sarcoma-Associated Herpesvirus

2.7.    Bacterias and Cancer

2.7.1.    Helicobacter Pylori

2.8.    Parasites and Cancer

2.8.1.    Schistosoma Haematobium
2.8.2.    Opisthorchis Viverrini

2.9.    Bacteria Allies Against Cancer

Module 3. Occupational Accident and Blood-borne Pathogens

3.1.    Epidemiology of Blood Borne Pathogen Infections

3.2.    Main Blood-Borne Infections

3.2.1.    Hepatitis B Virus Infection
3.2.2.    Hepatitis C Virus Infection
3.2.3.    HIV/AIDS

3.3.    Diagnostic and Therapeutic approach to Accidents Involving Blood

3.3.1.    Diagnostic Follow-up of Cases
3.3.2.    Treatment

3.4.    Universal Precautions in the Prevention of Accidents in the Workplace

3.5.    Biosafety Measures and the Role of the Epidemiologist in Reducing Biohazards
3.5.1.    Biological Risk
3.5.2.    Biosecurity

3.6.    Biosecurity Plans for Biological Protection

Module 4. Infections in the International Traveller

4.1.    Vaccines in the International Traveller

4.1.1.    Vaccines in the International Traveller
4.1.2.    Vaccination Against Yellow Fever

4.2.    Prophylaxis for Travellers to Tropical Areas

4.2.1.    Pharmacological Treatment According to the Geographical Area to be visited
4.2.2.    Glucose-6-- Phosphate Dehydrogenase Deficiency and Antimalarial Drugs
4.2.3.    Preventive Measures for Travellers in Tropical Areas

4.3.    Traveller's Diarrhoea

4.3.1.    Epidemiology
4.3.2.    Etiology
4.3.3.    Clinical manifestations
4.3.4.    Diagnosis
4.3.5.    Treatment

4.4.    Health Screening of International Travellers

4.5.    Fever on Return from International Travel

4.5.1.    Main Aetiologies
4.5.2.    Diagnostic Approach
4.5.3.    Imported Infectious Pathology in the International Traveller

Module 5. Chronic Non-Communicable Diseases and Infections

5.1.    Infections and the Chronic Inflammatory Response

5.1.1.    Immune System Cells of the Chronic Inflammatory Response to Infections
5.1.2.    The Granulomatous Response and Delayed-type Hypersensitivity
5.1.3.    The Role of Chemical Mediators of the Chronic Inflammatory Response

5.2.    Stress, Immunity and Infectious Agents

5.2.1.    Neurological, Endocrine and Immune Interrelationships
5.2.2.    Stress and the Immune Response
5.2.3.    Chronic Fatigue Syndrome and Infections

5.3.    Atherosclerosis, Cardiovascular Disease and the Role of Infectious Agents

5.3.1.    The Role of Infectious Agents in Atherosclerosis
5.3.2.    Cardiovascular Disease Mortality and its Association with Infectious Agents
5.3.3.    Cardiovascular Mortality in Patients with Pneumonia

5.4.    Digestive Diseases Associated with Infectious Microorganisms

5.4.1.    Gut Flora and its Important Functions
5.4.2.    Gastroduodenal Peptic Ulcer Disease and Helicobacter Pylori
5.4.3.    Inflammatory Bowel Disease and Infections
5.4.4.    Whipple’s Disease

5.5.    Neurological Diseases and Infections

5.5.1.    Dementia and Infections
5.5.2.    Multiple Sclerosis and its Relationship to Certain Infectious Agents
5.5.3.    Guillain-Barré Syndrome, Immunity and Viral Infections
5.5.4.    Parkinson’s Disease and its Association With Infections

5.6.    Endocrinopathies and Infections

5.6.1.    Diabetes Mellitus and Infections
5.6.2.    Chronic Thyroiditis and Infections

5.7.    The Infectious Theory of Rheumatic Diseases

5.7.1.    Rheumatoid Arthritis
5.7.2.    Systemic Lupus Erythematosus
5.7.3.    Seronegative Spondyloarthropathies
5.7.4.    Wegener's Granulomatosis
5.7.5.    Polymyalgia Rheumatica

Module 6. The Most Lethal Respiratory Infections

6.1.    Immunology and Defence Mechanisms of the Respiratory System

6.2.    Influenza and Other Lethal Viral Infections

6.2.1.    Influenza Epidemics
6.2.2.    H1N1 Influenza
6.2.3.    Vaccine Against Influenza and the Prevention of Mortality

6.3.    Bacterial Pneumonia: The Captain of the Armies of Death

6.3.1.    Community-Acquired Pneumonia (CAP)
6.3.2.    Intrahospital Pneumonia
6.3.3.    Pneumonia Associated With Healthcare

6.4.    Tuberculosis

6.4.1.    Epidemiology
6.4.2.    Pathobiology
6.4.3.    Classification
6.4.4.    Clinical Picture
6.4.5.    Diagnosis
6.4.6.    Treatment

6.5.    Loeffler's Syndrome and Eosinophilic Syndromes

6.5.1.    Pulmonary Phase of Parasites
6.5.2.    Clinical and Radiological Manifestations
6.5.3.    Other Eosinophilic Pneumonias

6.6.    Antimicrobials and the Respiratory System

6.6.1.    Antimicrobials Effective in the Respiratory System
6.6.2.    The Immunomodulatory Role of Macrolides in Pneumonia

Module 7.  Latest information on coronavirus infections

7.1.    Discovery and Evolution of Coronaviruses 

7.1.1.    Discovery of Coronaviruses
7.1.2.    Global Trends in Coronavirus Infections

7.2.    Main Microbiological characteristics and Members of the Coronavirus Family 

7.2.1.    General Microbiological Characteristics of Coronaviruses
7.2.2.    Viral Genome
7.2.3.    Principal Virulence Factors

7.3.    Epidemiological Changes in Coronavirus Infections from Discovery to the Present 

7.3.1.    Morbidity and Mortality of Coronavirus Infections from their Emergence to the Present

7.4.    The Immune System and Coronavirus Infections 

7.4.1.    Immunological Mechanisms Involved in the Immune Response to Coronaviruses
7.4.2.    Cytokine Storm in Coronavirus Infections and Immunopathology
7.4.3.    Modulation of the Immune System in Coronavirus Infections

7.5.    Pathogenesis and Pathophysiology of Coronavirus Infections

7.5.1.    Pathophysiological and Pathogenic Alterations in Coronavirus Infections
7.5.2.    Clinical Implications of the Main Pathophysiological Alterations

7.6.    Risk Groups and Transmission Mechanisms of Coronaviruses

7.6.1.    Main Sociodemographic and Epidemiological Characteristics of Risk Groups Affected by Coronavirus
7.6.2.    Coronavirus Mechanisms of Transmission

7.7.    Natural History of Coronavirus Infections

7.7.1.    Stages of Coronavirus Infection

7.8.    Latest Information on Microbiological Diagnosis of Coronavirus Infections 

7.8.1.    Sample Collection and Shipment
7.8.2.    PCR and Sequencing
7.8.3.    Serology Testing
7.8.4.    Virus Isolation

7.9.    Current Biosafety Measures in Microbiology Laboratories for Coronavirus Sample Handling

 7.9.1.    Biosafety Measures for Coronavirus Sample Handling

7.10.    Up-to-Date Management of Coronavirus Infections

7.10.1.    Prevention Measures
7.10.2.    Symptomatic Treatment
7.10.3.    Antiviral and Antimicrobial Treatment in Coronavirus Infections
7.10.4.    Treatment of Severe Clinical Forms

7.11.   Future Challenges in the Prevention, Diagnosis, and Treatment of Coronavirus

7.11.1.    Global Challenges for the Development of Prevention, Diagnostic, and Treatment Strategies for Coronavirus Infections

Module 8. Urinary Tract and Sexually Transmitted Infections

8.1.    Epidemiology of Urinary Tract Infection

8.1.1.    Factors Explaining the Increased Morbidity of Urinary Tract Infection in Women

8.2.    Immunology of the Urinary System

8.3.    Classification of Urinary Tract Infection

8.4.    Urinary Infection

8.4.1.    Etiology
8.4.2.    Clinical Picture
8.4.3.    Diagnosis
8.4.4.    Treatment

8.5.    Urinary Tract Infection in the Bladder Catheterised, Prostatic and Elderly Patient

8.6.    Most commonly used antimicrobials in urinary tract infections

8.6.1.    Pharmacological Elements
8.6.2.    Antimicrobial Resistance of the Main Bacteria Affecting the Urinary Tract

8.7.    Epidemiological Update on Major STIs

8.8.    Viral STIs

8.8.1.    Perinatal Herpes Simplex
8.8.2.    Viral Hepatitis
8.8.3.    Human papillomavirus
8.8.4.    HIV

8.9.    Bacterial STIs

8.9.1.    Gonorrhoea
8.9.2.    Syphilis
8.9.3.    Soft Chancre
8.9.4.    Lymphogranuloma Venereum

8.10.   Trichomoniasis and Genital Candidiasis

8.11.   Trichomoniasis: Epidemiology, Aetiology, Clinical Picture, Diagnosis and Treatment

8.12.   Genital Candidiasis: Epidemiology, Etiology, Clinical Picture, Diagnosis and Treatment

8.13.   The syndromic Approach to STIs and Control Measures

8.13.1.    Main Clinical Framework
8.13.2.    STI Control Measures

8.14.   Multidrug-Resistant Gonococcus: Treatment Alternatives

8.14.1.    Global Situation
8.14.2.    Alternative Treatments

8.15.  Current Management of Recurrent Herpes Infection

8.15.1.    Focus Latest Information of Recurrent Herpes Infection

Module 9. Food-Borne Infections

9.1.    Food-Borne Diseases, a Modern Day Health Problem

9.1.1.    Epidemiology
9.1.2.    Causes of Foodborne Infections

9.2.    Classification of Foodborne Infections

9.2.1.    Intoxications
9.2.2.    Infections
9.2.3.    Toxi-infections

9.3.    Main Aetiological Agents

9.3.1.    Salmonella
9.3.2.    Staphylococci
9.3.3.    Listeria monocytogenes
9.3.4.    Escherichia coli, 0157;H7
9.3.5.    Clostridium botulinum

9.4.    Foodborne Diseases and their Socio-Economic Impact

9.4.1.    Socio-Economic Consequences of the ATS

9.5.    Main Measures for the Control of Food-Borne Infections

9.5.1.    Primary Prevention of ATS
9.5.2.    Education of Health
9.5.3.    State Health Control and ATS

Module 10. Hepatitis and HIV/AIDS and TB Coinfection

10.1.   Viral Hepatitis A

10.1.1.    Virus Characteristics and Replication Cycle
10.1.2.    Clinical Picture
10.1.3.    Viral Markers
10.1.4.    Evolution and Prognosis
10.1.5.    Treatment

10.2.   Viral Hepatitis B and C

10.2.1.    Virus Characteristics and Replication Cycle
10.2.2.    Clinical Picture
10.2.3.    Viral Markers
10.2.4.    Evolution and Prognosis
10.2.5.    Treatment

10.3.   Viral Hepatitis D and E

10.3.1.    Virus Characteristics and Replication Cycle
10.3.2.    Clinical Picture
10.3.3.    Viral Markers
10.3.4.    Evolution and Prognosis
10.3.5.    Treatment

10.4.   Epidemiology of Morbidity and Mortality from TB/HIV/AIDS Coinfection

10.4.1.    Incidence
10.4.2.    Prevalence
10.4.3.    Mortality

10.5.   Pathobiology from TB/HIV/AIDS Coinfection

10.5.1.    Pathophysiological Alterations in Co-Infection
10.5.2.    Pathological Alterations

10.6.   Clinical Manifestations of Co-Infection

10.6.1.    Clinical Manifestations of Pulmonary TB
10.6.2.    Clinical Manifestations of Extrapulmonary TB

10.7.   Diagnosis of Tuberculosis in Patients Living with HIV/AIDS

10.7.1.    Diagnostic Studies in Pulmonary TB in HIV/AIDS Patients
10.7.2.    Diagnostic Studies in Pulmonary TB in HIV/AIDS Patients

10.8.   Integral Care of Patients with Co-infection TB and HIV/AIDS and Therapeutic Considerations

10.8.1.    The System of Comprehensive Care for TB/HIV/AIDS Patients
10.8.2.    Anti-Tuberculosis Treatment Considerations in Patients with TB/HIV/AIDS Co-Infection
10.8.3.    Anti-Tuberculosis Treatment Considerations in Patients with TB/HIV/AIDS Co-Infection
10.8.4.    The Issue of Anti-Tuberculosis and Anti-Retroviral Resistance in These Patients

Module 11. Viral Haemorrhagic Diseases and Arboviruses

11.1.   Viral Hemorrhagic Diseases

11.1.1.    Epidemiology
11.1.2.    Classification
11.1.3.    Diagnostic Approach to Viral Haemorrhagic Diseases
11.1.4.    The Development of Vaccines for New Diseases
11.1.5.    Measures for the Control of Viral Haemorrhagic Diseases

11.2.   Ebola Haemorrhagic Fever

11.2.1.    Characteristics and Replicative Cycle of the Virus
11.2.2.    Clinical Picture
11.2.3.    Diagnosis
11.2.4.    Treatment

11.3.   South American Hemorrhagic Fevers

11.3.1.    Characteristics and Replicative Cycle of the Virus
11.3.2.    Clinical Picture
11.3.3.    Diagnosis
11.3.4.    Treatment

11.4.    Arbovirus:

11.4.1.    Epidemiology
11.4.2.    Vector Control
11.4.3.    Other Arboviruses

11.5.   Yellow fever.

11.5.1.    Concept
11.5.2.    Replicative Cycle of the Virus
11.5.3.    Clinical manifestations
11.5.4.    Diagnosis
11.5.5.    Treatment

11.6.   Dengue.

11.6.1.    Concept
11.6.2.    Replicative Cycle of the Virus
11.6.3.    Clinical manifestations
11.6.4.    Diagnosis
11.6.5.    Treatment

11.7.    Chikungunya

11.7.1.    Concept
11.7.2.    Replicative Cycle of the Virus
11.7.3.    Clinical manifestations
11.7.4.    Diagnosis
11.7.5.    Treatment

11.8.   Zika

11.8.1.    Concept
11.8.2.    Replicative Cycle of the Virus
11.8.3.    Clinical manifestations
11.8.4.    Diagnosis
11.8.5.    Treatment

Module 12. Central Nervous System Infections

12.1.   The Immune Defence Mechanisms of the CNS

12.1.1.    Defence Mechanisms of the CNS
12.1.2.    The Immune Response in the CNS

12.2.   Epidemiology of the CNS Infection

12.2.1.    Morbidity
12.2.2.    Mortality
12.2.3.    Risk factors

12.3.   Microbiological Diagnosis of the CNS Infection

12.3.1.    The Study of Cerebrospinal Fluid

12.4.   Meningitis

12.4.1.    Etiology
12.4.2.    Clinical Picture
12.4.3.    Diagnosis
12.4.4.    Treatment

12.5.   Encephalitis

12.5.1.    Etiology
12.5.2.    Clinical Picture
12.5.3.    Diagnosis
12.5.4.    Treatment

12.6.   Myelitis

12.6.1.    Etiology
12.6.2.    Clinical Picture
12.6.3.    Diagnosis
12.6.4.    Treatment

12.7.   Antibiotics and the Blood-Brain Barrier

12.7.1.    The Role of the Blood-Brain Barrier
12.7.2.    The Crossing of the Blood-Brain Barrier by Antibiotics

Module 13. Zoonosis

13.1.   Overview of Zoonosis

13.1.1.    General Concepts and Epidemiology of Zoonoses
13.1.2.    Main Zoonotic Diseases on an International Level
13.1.3.    Prion Zoonosis
13.1.4.    Prions in the Aetiology of Diseases
13.1.5.    Bovine Spongiform Encephalopathy (or mad cow disease)
13.1.6.    Main Zoonosis Control Measures

13.2.   Rabies

13.2.1.    Epidemiology
13.2.2.    Infectious Agents
13.2.3.    Pathobiology
13.2.4.    Clinical Picture
13.2.5.    Diagnosis
13.2.6.    Treatment

13.3.   Bird Flue

13.3.1.    Epidemiology
13.3.2.    Infectious Agents
13.3.3.    Pathobiology.
13.3.4.    Clinical Picture
13.3.5.    Diagnosis
13.3.6.    Treatment

13.4.   Leptospirosis

13.4.1.    Epidemiology
13.4.2.    Infectious Agents
13.4.3.    Pathobiology
13.4.4.    Clinical Picture
13.4.5.    Diagnosis
13.4.6.    Treatment

13.5.   Brucellosis

13.5.1.    Epidemiology
13.5.2.    Infectious Agents
13.5.3.    Pathobiology
13.5.4.    Clinical Picture
13.5.5.    Diagnosis
13.5.6.    Treatment

13.6.   Toxoplasmosis

13.6.1.    Epidemiology
13.6.2    Infectious Agent
13.6.3.    Pathobiology
13.6.4.    Clinical Picture
13.6.5.    Diagnosis
13.6.6.    Treatment

Module 14. Mycobacteriosis and anaerobic infections

14.1.   General Overview of Mycobacteriosis

14.1.1.    Microbiological Characteristics of Mycobacteria
14.1.2.    Immune Response to Mycobacterial Infection
14.1.3.    Epidemiology of Major Nontuberculous Mycobacteria Infections

14.2.   Microbiological Methods for the Diagnosis of Mycobacterioses

14.2.1.    Direct Methods.
14.2.2.    Indirect Methods

14.3.   Intracellular Mycobacterium Avium Infection

14.3.1.    Epidemiology
14.3.2.    Infectious Agents
14.3.3.    Pathobiology.
14.3.4.    Clinical Picture
14.3.5.    Diagnosis
14.3.6.    Treatment

14.4.   Infection by Mycobacterium Kansasii

14.4.1.    Epidemiology
14.4.2.    Infectious Agents
14.4.3.    Pathobiology.
14.4.4.    Clinical Picture
14.4.5.    Diagnosis
14.4.6.    Treatment

14.5.   Leprosy

14.5.1.    Epidemiology
14.5.2.    Infectious Agents
14.5.3.    Pathobiology.
14.5.4.    Clinical Picture
14.5.5.    Diagnosis
14.5.6.    Treatment

14.6.    Other Mycobacteriosis

14.7.   Antimycobacterials

14.7.1.    Pharmacological Characteristics
14.7.2.    Clinical Use

14.8.   Microbiological Characteristics of Anaerobic Germs

14.8.1.    Microbiological Characteristics of Anaerobic Germs
14.8.2.    Microbiological Studies

14.9.   Pulmonary Abscess

14.9.1.    Definition
14.9.2.    Etiology
14.9.3.    Clinical Picture
14.9.4.    Diagnosis
14.9.5.    Treatment

14.10. Intra-abdominal and ovarian tube abscesses

14.10.1.    Definition
14.10.2.    Etiology
14.10.3.    Clinical Picture
14.10.4.    Diagnosis
14.10.5.    Treatment

14.11. Intracerebral Abscess

14.11.1.    Definition
14.11.2.    Etiology
14.11.3.    Clinical Picture
14.11.4.    Diagnosis
14.11.5.    Treatment

14.12. Tetanus and Gangrene

14.12.1.    Tetanus: Neonatal and Adult
14.12.2.    Gangrene: Definition, Aetiology, Clinical picture, Diagnosis, Treatment

14.13. Main Antimicrobials against Anaerobic Germs

14.13.1.    Mechanism of Action
14.13.2.    Pharmacokinetics
14.13.3.    Dose
14.13.4.    Introduction
14.13.5.    Adverse Effects

Module 15. Mycoses and Parasitosis in Infectiology

15.1.  General Information on Fungi

15.1.1.    General Features of Fungi
15.1.2.    Immune Response to Fungi

15.2.   Diagnostic Methods for Mycoses

15.2.1.    Direct Methods
15.2.2.    Indirect Methods

15.3.   Superficial Mycosis: Tinea and Epidermatophytosis

15.3.1.    Definition
15.3.2.    Etiology
15.3.3.    Clinical Picture
15.3.4.    Diagnosis
15.3.5.    Treatment

15.4.   Deep Mycosis

15.4.1.    Cryptococcosis
15.4.2.    Histoplasmosis
15.4.3.    Aspergillosis
15.4.4.    Other Mycosis

15.5.   Update on Antifungals

15.5.1.    Pharmacological Elements
15.5.2.    Clinical Use

15.6.   General overview of parasitic diseases

15.6.1.    General Features of Microbiological Parasites
15.6.2.    Immune Response to Parasites
15.6.3.    Immune Response to Protozoa
15.6.4.    Immune Response to Helminths

15.7.   Diagnostic Methods for Parasites

15.7.1.    Diagnostic Methods for Protozoa
15.7.2.    Diagnostic Methods for Helminths

15.8.   Intestinal Parasites

15.8.1.    Ascariasis
15.8.2.    Oxiuriasis
15.8.3.    Hookworm Disease and Necatoriasis
15.8.4.    Trichuriasis

15.9.   Tissue Parasitosis

15.9.1.    Malaria
15.9.2.    Trypanosomiasis
15.9.3.    Schistosomiasis
15.9.4.    Leishmaniasis
15.9.5.    Filariasis

15.10. Update on Antiparasitics

15.10.1.    Pharmacological Elements
15.10.2.    Clinical Use

Module 16. Multi-Resistance and Vaccines

16.1.  The Silent Epidemic of Antibiotic Resistance

16.1.1.    Globalisation and Resistance
16.1.2.    Change from Susceptible to Resistant of the Microorganisms

16.2.   The Main Genetic Mechanisms of Antimicrobial Resistance

16.2.1.    Describe the Main Mechanisms of Antimicrobial Resistance
16.2.2.    Selective Antimicrobial Pressure on Antimicrobial Resistance

16.3.   Superbugs

16.3.1.    Pneumococcus Resistant to Penicillin and Macrolides
16.3.2.    Multidrug-Resistant Staphylococci
16.3.3.    Resistant Infections in Intensive Care Units (ICUs)
16.3.4.    Resistant Urinary Tract Infections
16.3.5.    Other Multi-Resistant Microorganisms

16.4.   Resistant Viruses

16.4.1.    HIV
16.4.2.    Influenza
16.4.3.    Hepatitis Viruses

16.5.   Multidrug-Resistant Malaria

16.5.1.    Chloroquine Resistance
16.5.2.    Resistance to Other Antimalarials

16.6.   The Main Genetic Studies of Antimicrobial Resistance

16.6.1.    Interpretation of Resistance Studies

16.7.  Global Strategies for Reducing Antimicrobial Resistance

16.7.1.    The Control of Prescribing Antibiotics
16.7.2.    Microbiological Mapping and Clinical Practice Guidelines

16.8.   Overview of Vaccines

16.8.1.    Immunological Basis of Vaccination
16.8.2.    The Process of Vaccination Production
16.8.3.    Quality Control of Vaccines
16.8.4.    Vaccine Safety and Major Adverse Events
16.8.5.    Clinical and Epidemiological Studies for Vaccine Approval

16.9.   The Use of Vaccines

16.9.1.    Vaccine-Preventable Diseases and Vaccination Programmes
16.9.2.    Global Experiences of the Effectiveness of Vaccination Programmes
16.9.3.    Vaccine Candidates for New Diseases

Module 17. Rare Infectious Diseases and Other Challenges in Infectiology

17.1.  Overview of Rare Infectious Diseases

17.1.1.    General Concepts
17.1.2.    Epidemiology of Rare or Uncommon Infectious Diseases

17.2.   Bubonic Plague

17.2.1.    Definition
17.2.2.    Etiology
17.2.3.    Clinical Picture
17.2.4.    Diagnosis
17.2.5.    Treatment

17.3.    Lyme Disease

17.3.1.    Definition
17.3.2.    Etiology
17.3.3.    Clinical Picture
17.3.4.    Diagnosis
17.3.5.    Treatment

17.4.   Babesiosis

17.4.1.    Definition
17.4.2.    Etiology
17.4.3.    Clinical Picture
17.4.4.    Diagnosis
17.4.5.    Treatment

17.5.   Rift Valley Fever

17.5.1.    Definition
17.5.2.    Etiology
17.5.3.    Clinical Picture
17.5.4.    Diagnosis
17.5.5.    Treatment

17.6.   Diphyllobothriasis

17.6.1.    Definition
17.6.2.    Etiology
17.6.3.    Clinical Picture
17.6.4.    Diagnosis
17.6.5.    Treatment

17.7.   Zygomycosis

17.7.1.    Definition
17.7.2.    Etiology
17.7.3.    Clinical Picture
17.7.4.    Diagnosis
17.7.5.    Treatment

17.8.   Cysticercosis

17.8.1.    Definition
17.8.2.    Etiology
17.8.3.    Clinical Picture
17.8.4.    Diagnosis
17.8.5.    Treatment

17.9.   Kuru

17.9.1.    Definition
17.9.2.    Etiology
17.9.3.    Clinical Picture
17.9.4.    Diagnosis
17.9.5.    Treatment

17.10.    The Re-emergence of Old Diseases: Causes and Effects

17.10.1.    Emerging and New Infectious Diseases that Demand New Approaches to their Control
17.10.2.    The Rise of Microbiological Resistance to Antimicrobial Drugs
17.10.3.    Development of New Antibiotics
17.10.4.     Training and Success of Infectologists

Diagnose possible microbes that cause infections in the CNS by studying cerebrospinal fluid"